Clinical Pharmacy and Pharm.D Forums
Welcome to our forum!

Kindly register and be a part of our group...

For any concerns, write your comment in Help Forum below.

Have a nice time Smile
Clinical Pharmacy and Pharm.D Forums
HomeCalendarGalleryFAQSearchRegisterMemberlistUsergroupsLog in

Share | 

 New Recommendations for the Management of Diabetes and CVD

Go down 


Number of posts : 112
Registration date : 2006-12-09

PostSubject: New Recommendations for the Management of Diabetes and CVD   Sat Feb 17, 2007 11:19 pm

The recommendations suggest that patients with coronary artery disease should have an oral glucose tolerance test if their diabetic status is unknown. "Diabetes or prediabetes is painless and remains undetected if not looked for," he adds. "Certain people are at higher risk than others (family history, overweight, previous gestational diabetes to mention a few). Thus we need to screen for elevated glucose (prediabetes) and prevent the progress at an early stage." This point is emphasized and the methods for screening are outlined in the guidelines, he notes.

And Do Not Forget the Diabetic Patients With Coronary Heart Disease

The recommendations also advise that every patient with diabetes should be screened for CAD, Dr. Ryden notes, adding that diabetes specialists do not understand coronary heart disease.

The other co-chair of the task force Eberhard Standl, MD, of the Munich Schwabing Hospital in Munich, Germany, said, "We are dealing with two sides of the same coin: diabetes on one side and cardiovascular diseases on the other. The great merit of these guidelines is that they recognize this. We hope they will improve the management and care of millions of patients who have both cardiovascular and metabolic diseases in common."

Study Highlights

  • Diabetes may be defined by a fasting glucose level of 126 mg/dL or greater or a 2-hour postload plasma glucose level of 200 mg/dL or greater. Most patients with incipient diabetes do not have both of these abnormalities present simultaneously.
  • While 50% of patients with diabetes have yet to be diagnosed with this disorder, mass screening for diabetes has not been recommended. However, targeted screening for patients at high risk of developing diabetes or with a history of cardiovascular disease should be considered.
  • Postprandial glucose levels are particularly related to the risk for future cardiovascular disease compared with fasting glucose levels. However, few studies have addressed the issue of whether reducing postprandial glucose reduces the risk for cardiovascular disease. The research that has been performed has yielded moderately positive results in reducing cardiovascular events.
  • Diabetes also increases the risk for cerebrovascular disease by 3- to 5-fold. Treatment of hypertension with a renin-angiotensin-system inhibitor may afford an augmented reduction in the risk for stroke among diabetic patients.
  • Physical exercise, diet control, weight loss, metformin, and rosiglitazone have been demonstrated to reduce the progression of impaired glucose tolerance to overt diabetes.
  • The goal for glycated hemoglobin levels among patients with diabetes is 6.5% or less. Metformin is a first-line medication for overweight patients with type 2 diabetes, and clinicians should augment therapy rapidly to reduce glucose values to target levels.
  • Statin therapy should be initiated for all patients without contraindications to medications who have diabetes and cardiovascular disease, with a low-density lipoprotein cholesterol goal level of 70 to 77 mg/dL. Patients with diabetes but no history of cardiovascular disease should receive statins if the total cholesterol level exceeds 135 mg/dL, and these patients should be treated to reduce low-density lipoprotein cholesterol levels by 30% to 40%. All patients with type 1 diabetes who are older than 40 years should be considered for statin therapy regardless of baseline cholesterol levels, and patients with type 1 diabetes between the ages of 18 and 39 years should be considered for statin therapy if they have additional cardiovascular risk factors.
  • Blood pressure should be lowered to less than 130/80 mm Hg among patients with diabetes. Treatment should include a renin-angiotensin-system inhibitor.
  • Treatment of coronary heart disease among patients with diabetes should not differ significantly from treatment of patient without diabetes. Both groups should receive similar doses of aspirin and beta-blocker medications, and clopidogrel may be considered as an additional treatment. Angiotensin-converting enzyme inhibitors can reduce the risk for further cardiovascular events among patients with diabetes and established cardiovascular disease.
  • Generally, coronary artery bypass grafting is associated with reduced rates of revascularization compared with percutaneous coronary intervention among patients with diabetes. Elective percutaneous coronary intervention should include treatment with glycoprotein IIb/IIIa inhibitors among patients with diabetes.
-Treatment with warfarin with a target international normalized ratio of 2 to 3 should be considered for all patients with diabetes and atrial fibrillation
Back to top Go down
View user profile
khalid m.

Number of posts : 1
Registration date : 2007-03-26

PostSubject: Re: New Recommendations for the Management of Diabetes and CVD   Mon Mar 26, 2007 11:29 pm

please can you send me the full study to my email
i am a jordaninan pharmacist studying MS C in pharmacy in uk my phone noumber 00447894472080
my email
Back to top Go down
View user profile
New Recommendations for the Management of Diabetes and CVD
Back to top 
Page 1 of 1
 Similar topics
» Building Management and Security
» My little boy going for diabetes tests tomorrow
» Project Procurement Management Plan
» Hand Manifestations of Diabetes Mellitus

Permissions in this forum:You cannot reply to topics in this forum
Clinical Pharmacy and Pharm.D Forums :: Clinical Clerkship Rotations :: Endocrine & GIT-
Jump to: